Aduro Biotech Slumps 9% on Partial Clinical Hold to Pause New Patient Enrollment in LADD Study

Aduro Biotech (ADRO) is down 9% after the company said it received notice from the U.S. Food and Drug Administration (FDA) that trials with investigational agents based on its LADD (Listeria-based immunotherapy construct) platform have been placed on partial clinical hold to pause new patient enrollment.

The partial hold was initiated after the FDA was notified a blood culture sample from an indwelling port of a metastatic pancreatic cancer patient who presented with gastrointestinal symptoms tested positive for Listeria, which is suspected to be CRS-207. The patient was administered intravenous antibiotics, subsequent blood cultures tested negative for Listeria, and the patient was reported to be doing well.

The company said it’s revising study protocols in accordance with feedback from the FDA, including modification of antibiotic administration following treatment, extended patient surveillance, and, as a pre-emptive measure, exclusion of patients who are on or will receive certain immune-suppressive treatments or who have certain prosthetic devices. Aduro said it will provide proposed revisions to the protocols, patient consent forms, and investigator brochures to the agency later this week.

Leave a Comment